NCT05952947View on ClinicalTrials.gov

HRYZ-T101 Injection for HPV18 Positive Solid Tumor

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

February 29, 2028

Conditions
Cervical CancerHead and Neck Squamous Cell CarcinomaCarcinoma of VaginaCarcinoma of PenisAnal CancerCarcinoma of Vulva
Interventions
BIOLOGICAL

HRYZ-T101 Injection

On day 1, the TCR-T cells will be administered intravenously.

DRUG

Fludarabine + Cyclophosphamide

Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors

Lead Sponsor

HRYZ Biotech Co.
All Listed Sponsors
lead

HRYZ Biotech Co.

INDUSTRY

NCT05952947 - HRYZ-T101 Injection for HPV18 Positive Solid Tumor | Biotech Hunter | Biotech Hunter